These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 27129125

  • 1. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.
    Klamerus KJ, Alvey C, Li L, Feng B, Wang R, Kaplan I, Shi H, Dowty ME, Krishnaswami S.
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):499-507. PubMed ID: 27129125
    [Abstract] [Full Text] [Related]

  • 2. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Krishnaswami S, Boy M, Chow V, Chan G.
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
    [Abstract] [Full Text] [Related]

  • 3. Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers.
    Krishnaswami S, Wang T, Yuan Y, Alvey CW, Checchio T, Peterson M, Shi H, Riese R.
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):395-9. PubMed ID: 27137149
    [Abstract] [Full Text] [Related]

  • 4. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
    Lawendy N, Lamba M, Chan G, Wang R, Alvey CW, Krishnaswami S.
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):421-7. PubMed ID: 27129117
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
    Müller F, Pontones CA, Renner B, Mieth M, Hoier E, Auge D, Maas R, Zolk O, Fromm MF.
    Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
    [Abstract] [Full Text] [Related]

  • 8. Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET.
    Raychaudhuri S, Abria C, Harmany ZT, Smith CM, Kundu-Raychaudhuri S, Raychaudhuri SP, Chaudhari AJ.
    Int J Rheum Dis; 2019 Dec; 22(12):2165-2169. PubMed ID: 31659868
    [Abstract] [Full Text] [Related]

  • 9. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
    Lamba M, Wang R, Fletcher T, Alvey C, Kushner J, Stock TC.
    J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526
    [Abstract] [Full Text] [Related]

  • 10. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
    Shi R, Xu Z, Xu X, Jin J, Zhao Y, Wang T, Li Y, Ma Y.
    Eur J Pharm Sci; 2019 Jan 15; 127():282-290. PubMed ID: 30428337
    [Abstract] [Full Text] [Related]

  • 11. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
    Topletz-Erickson AR, Lee AJ, Mayor JG, Rustia EL, Abdulrasool LI, Wise AL, Dailey B, DeChenne S, Walker LN, Alley SC, Endres CJ.
    J Clin Pharmacol; 2021 Apr 15; 61(4):461-471. PubMed ID: 32989831
    [Abstract] [Full Text] [Related]

  • 12. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
    Shibata M, Toyoshima J, Kaneko Y, Oda K, Nishimura T.
    Eur J Clin Pharmacol; 2020 Aug 15; 76(8):1135-1141. PubMed ID: 32472157
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A Drug-Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2- and MATE1-Mediated Transport of Metformin in Healthy Participants.
    Bhardwaj R, Morris B, Matschke K, Bertz R, Croop R, Liu J.
    Clin Pharmacol Drug Dev; 2024 May 15; 13(5):465-473. PubMed ID: 38174905
    [Abstract] [Full Text] [Related]

  • 15. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
    Huang F, Luo ZC.
    Clin Rheumatol; 2019 Feb 15; 38(2):523-534. PubMed ID: 30242639
    [Abstract] [Full Text] [Related]

  • 16. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
    Nishizawa K, Yoda N, Morokado F, Komori H, Nakanishi T, Tamai I.
    PLoS One; 2019 Feb 15; 14(4):e0214862. PubMed ID: 30951542
    [Abstract] [Full Text] [Related]

  • 17. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
    Ogasawara K, Wood-Horrall RN, Thomas M, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G.
    Cancer Chemother Pharmacol; 2021 Dec 15; 88(6):941-952. PubMed ID: 34477937
    [Abstract] [Full Text] [Related]

  • 18. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
    Gupta P, Alvey C, Wang R, Dowty ME, Fahmi OA, Walsky RL, Riese RJ, Krishnaswami S.
    Br J Clin Pharmacol; 2012 Jul 15; 74(1):109-15. PubMed ID: 22233204
    [Abstract] [Full Text] [Related]

  • 19. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
    Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S.
    J Am Acad Dermatol; 2016 May 15; 74(5):841-50. PubMed ID: 26899199
    [Abstract] [Full Text] [Related]

  • 20. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
    Choi HY, Noh YH, Kim YH, Kim MJ, Lee SH, Kim JA, Kim B, Lim HS, Bae KS.
    Int J Clin Pharmacol Ther; 2014 May 15; 52(5):381-91. PubMed ID: 24495314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.